The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.